Additive BioFabrication – 3D Printing for Pharmaceutical Applications and Regenerative Medicine

Seminar | October 24 | 11 a.m.-12 p.m. | 3110 Etcheverry Hall

 Professor Felicity Rose & Professor Ricky Wildman, University of Nottingham, UK

 Department of Mechanical Engineering (ME)

Abstract: The industrial uptake of Additive Manufacturing and 3D printing processes is growing rapidly but is being hampered by the lack of breadth of materials usable in such systems. Identifying, and then optimisating formulations for 3D printing is time consuming, and generally involves many tedious steps each of which require lengthy analysis. We have developed a methodology that compresses and automates the formulation steps. In addition, we incorporate assays that assess final material and product characteristics, such that screening can occur at all steps of the manufacturing workflow. Through our research, we show how suitable choice of high throughput and fast assay methods can reduce the time for formulation of a 3D printed resin by a factor of 15, raising the possibility of ‘dialling up’ materials ready for bespoke product manufacture. We demonstrate our recent findings in materials formulation for additive manufacturing within the context of biomedical applications, specifically towards the next generation of pharmaceuticals.

At Nottingham, we have led the field of biomaterials development for musculoskeletal tissue regeneration for over 15 years. We have invented and commercialised new systems for the delivery of biopharmaceuticals and specifically for the delivery of stem cells and growth factors to support new bone formation. Our research has focussed on the use of synthetic, biodegradable polymers for this purpose and in particular the control of scaffold architectures and controlled release of growth factors from microparticles to support 3D tissue growth. We have worked closely with clinicians to enhance the applicability of these materials within the clinic. We are now expanding our research through the application of additive manufacturing to regenerative medicine. We intend to exploit the geometrical freedom offered by additive manufacturing approaches to understanding the role of geometry on cell behaviour by using engineered topographies and 3D architectures. We believe that this approach will identify new materials and geometries, within a manufacturing context, that interact with their biological environment and enhance the regenerative process.

In our seminar, we will summarise these research areas and open opportunities to explore new collaborations in both basic research and translational medicine.

Biographies: Felicity Rose is Professor of Biomaterials and Tissue Engineering and is Head of the Division of Regenerative Medicine and Cellular Therapies, School of Pharmacy (Faculty of Science) at Nottingham. With an established reputation in the UK and internationally as one of the research leaders in regenerative medicine, she is co-lead of the largest network of research funding in biomaterials development within the UK. This includes two Engineering and Physical Sciences Research Council (EPSRC) programme grants and the UK Regenerative Medicine Platform (UKRMP2) smart materials hub contributing to over £10M current research funding (£2.5M Nottingham). She has an established track record (H index 35) through publication in high impact journals including PNAS, Advanced Materials and Biomaterials. She actively contributes to the regenerative medicine research community through committee membership (elected) of the Tissue and Cell Engineering Society (TCES; UK) and Tissue Engineering and Regenerative Medicine International Society (TERMis – EU). She sits on the Scientific Advisory Committee for the TERMis World Congress 2021, Maastricht.

Ricky Wildman is Professor of Multiphase Flow and Engineering in the Faculty of Engineering. Since 2012, his focus has been the building of scientific understanding of additive manufacturing processes in order to exercise control over function, and to extend the application of additive manufacturing to areas beyond the traditional fields of aerospace and automotive. These efforts have resulted in PI income in excess of £5M and involvement in projects as CoI of over £110M. He has published over 130 articles (H index 32). More recently, he has built an interconnected and interdisciplinary team that seeks to exploit the freedoms of additive manufacturing in healthcare, in particular in the areas of drug delivery and control over biological systems. This has resulted in a series of articles that exemplify the benefits that additive manufacture has for drug delivery, including Louzao et al ACS Applied Materials and Interfaces 2018, Khaled et al International Journal of Pharmaceutics 2018, Khaled et al AAPS Pharmaceutical Science and Technology, and Cader et al International Journal of Pharmaceutics 2109. This body of work led to and then was supported by two significant PI grants, firstly from GSK 3D printed solid dosage forms (£850k) and then EPSRC Formulation for 3D Printing (£3.5M)/Industry (£300k) EP/N024818. In 2014, Ricky co-founded a spin out company, Added Scientific Ltd which provides technical services for companies wishing to understand how to implement additive manufacturing solutions.

 hkt@berkeley.edu, 510-642-4901